Magnafolate
Commercial- Indications
- Folate deficiency, Pregnancy support
Company intelligence / Profile preview
Hexin (Suzhou) Pharmaceutical Technology Co Ltd. is a private Chinese pharmaceutical company founded in Jiangsu province in 2020. The company develops peptide-based diagnostic radiopharmaceuticals for oncology imaging applications. Its lead candidate, 68Ga-HX01—a peptide conjugate radionuclide targeting APN and αvβ3—is currently undergoing Phase I clinical trials for PET imaging of malignant solid neoplasms. Early-stage studies are focused on evaluating safety, biodistribution, radiation dose and pharmacokinetics in healthy volunteers and cancer patients[1].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hexin (Suzhou) Pharmaceutical Technology Co Ltd..